CRT

Trail Carbon Capture Pilot Plant Now Operational 

Retrieved on: 
Wednesday, December 20, 2023
Carbon, Tubing (recreation), Teck Resources, Acid, Recycling, Government, Glass, Form, Columbia, News, CCUS, Climate change, Carbon dioxide, CRT, TSX, CO2, Data collection, Renewable energy

TRAIL, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the Carbon Capture Pilot Plant at its Trail Operations in southern British Columbia is now operating and successfully capturing carbon dioxide (CO2).

Key Points: 
  • TRAIL, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the Carbon Capture Pilot Plant at its Trail Operations in southern British Columbia is now operating and successfully capturing carbon dioxide (CO2).
  • “This project is part of Teck’s ongoing work to take action on climate change and achieve our long-term goal of net-zero operations by 2050.”
    The Carbon Capture Pilot Plant separates CO2 from the Acid Plant flue gas at Trail Operations at a rate of one tonne per day and will operate through 2024 for testing and data collection purposes.
  • Teck’s Carbon Capture Utilization and Storage (CCUS) pilot project is also evaluating options for the utilization and/or storage of the captured CO2 at Trail Operations.
  • Teck acknowledges the support of the CleanBC Industry Fund for its funding contribution towards the CCUS Pilot Plant Feasibility Study and development of a CO2 storage pilot project.

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

Retrieved on: 
Monday, November 20, 2023
Sale, Institute of Cancer Research, Translation, Research, AstraZeneca, Food, US Foods, PIK3CA, Mouse, Patient, PTEN, FDA, PKB, Marketing, Neoplasm, CRT, Therapy, US FDA, Drug discovery, AKT, Cancer, 3D, AKT1, Central nervous system, Recurrence, ICR, Pharmaceutical industry, Astex Pharmaceuticals

CAMBRIDGE, United Kingdom, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it is in line to receive a milestone payment from AstraZeneca on first commercial sale of the drug in the US and royalties from AstraZeneca on future sales following the US Food and Drug Administration’s (FDA) approval of Truqap™ plus Faslodex® as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

Key Points: 
  • This is the third cancer drug in the last five years to reach market approval that has been discovered and developed under, or subsequent to, an Astex drug discovery collaboration.
  • Truqap was discovered by AstraZeneca following an earlier drug discovery research collaboration between Astex, The Institute of Cancer Research, London, and Cancer Research Technology (CRT; now Cancer Research Horizons) that was signed in 2003.
  • In 2010, AstraZeneca announced its discovery of Truqap, and began to develop the drug as a potential treatment for various forms of cancer.
  • This is also a great example of UK Biotech-Academia-Pharma collaboration and underlines the strength of the UK life sciences ecosystem.”
    Graphic of the hat-trick of three marketed cancer drugs discovered and developed under, or subsequent to, an Astex drug discovery collaboration with pharma

Enact Completes Sixth Mortgage Insurance Linked Note Credit Risk Transaction as Part of its Diversified Credit Risk Transfer Program

Retrieved on: 
Wednesday, November 15, 2023
ACT, Security (finance), Annual report, Government, Insurance, Federal Housing Administration, Triangle, ILN, GSE, Fannie Mae, Uncertainty, CRT, Communication, Risk, Freddie Mac, Failure, COVID-19, Enactment

This ILN transaction provides coverage on a portfolio of existing seasoned mortgage insurance policies written from July 1, 2022 through June 30, 2023.

Key Points: 
  • This ILN transaction provides coverage on a portfolio of existing seasoned mortgage insurance policies written from July 1, 2022 through June 30, 2023.
  • Triangle Re 2023-1 funded its reinsurance obligations by issuing four classes of mortgage ILNs, which have a 10-year legal maturity and a 5-year call option to qualified institutional investors in an unregistered private offering.
  • The ILNs are non-recourse to Enact Holdings, Inc., or its subsidiaries and affiliates.
  • Our forward-looking statements contained herein speak only as of the date of this press release.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

KBRA Releases Research – 2024 RMBS Sector Outlook: Holding Steady With a Little Upside

Retrieved on: 
Monday, November 20, 2023
Finance, Other Construction & Property, Professional Services, Residential Building & Real Estate, Construction & Property, KBRA, CRT, LTV, Yoy, RMBS, FY, YTD

KBRA releases its 2024 RMBS Sector Outlook, which provides an update on key U.S. RMBS market and performance themes as of year-to-date (YTD) 2023, as well as issuance volume trends and forecasts for 2024, collateral performance trends, and rating surveillance outcomes.

Key Points: 
  • KBRA releases its 2024 RMBS Sector Outlook, which provides an update on key U.S. RMBS market and performance themes as of year-to-date (YTD) 2023, as well as issuance volume trends and forecasts for 2024, collateral performance trends, and rating surveillance outcomes.
  • In addition, we cover the RMBS 2.0 spread environment at pricing, plus other themes to watch in 2024.
  • RMBS 2.0 Spreads: The spread environment in 2023 YTD continued to exhibit volatility, with levels that were generally unfavorable across all sectors of RMBS.
  • Recent RMBS 2.0 Performance Trends: RMBS 2.0 YTD 2023 exhibited generally stable credit performance across all sectors.

Fannie Mae Announces 2024 Connecticut Avenue Securities (CAS) Issuance Calendar

Retrieved on: 
Wednesday, December 13, 2023
Transfer, Calendar, Fannie Mae, CAS, CRT, LTV, OTCQB, FNMA

WASHINGTON, Dec. 13, 2023 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) announced today its 2024 Connecticut Avenue Securities® (CAS) Issuance Calendar as part of its efforts to ensure transparency in the market.

Key Points: 
  • WASHINGTON, Dec. 13, 2023 /PRNewswire/ -- Fannie Mae (OTCQB: FNMA) announced today its 2024 Connecticut Avenue Securities® (CAS) Issuance Calendar as part of its efforts to ensure transparency in the market.
  • Fannie Mae has the option to issue, or forgo issuance of, one or more CAS deals during each window.
  • "Fannie Mae will be dynamic in its strategic approach to CRT issuance in 2024.
  • We currently expect total CAS volume of around $4 billion across 5-7 transactions, reflecting reduced single-family mortgage loan acquisitions in 2023," said Kathleen Pagliaro, Vice President of Credit Risk Transfer, Fannie Mae.

SXSW EDU® Announces Opening Keynote and Additional Featured Sessions for the 2024 Conference & Festival

Retrieved on: 
Wednesday, December 13, 2023
Civic, Congressional Black Caucus Foundation, Empowerment, Associate, Harlem Children's Zone, Policy, Innovation, AmeriCorps, Keynote, Conditional sentence, USA Today, History, Student, Research, CRT, Stanford University, SXSW, Critical race theory, African American Policy Forum, Mentorship, Poverty, Geoffrey Canada, Rutgers University, Teacher, Good, Education, Tutoring, Management, School

AUSTIN, Texas, Dec. 13, 2023 /PRNewswire/ -- SXSW EDU® is excited to continue building out the lineup for its upcoming conference and festival with the addition of an Opening Keynote on the debate over and misconceptions of Critical Race Theory (CRT). Featuring co-founder and executive director of The African American Policy Forum, Dr. Kimberlé Crenshaw, and vice president of the Center for Policy Analysis & Research at the Congressional Black Caucus Foundation, Dr. Jonathan Cox, the Keynote – presented as a fireside chat – invites attendees to explore the conceptual overview of CRT as well as the significance of integrating it into academia.

Key Points: 
  • AUSTIN, Texas, Dec. 13, 2023 /PRNewswire/ -- SXSW EDU® is excited to continue building out the lineup for its upcoming conference and festival with the addition of an Opening Keynote on the debate over and misconceptions of Critical Race Theory (CRT).
  • "SXSW EDU's mission has always been to offer discussions and perspectives on the matters impacting the state of education.
  • Because Critical Race Theory remains a significant topic in the field, it is fitting to open our 2024 conference and festival with a comprehensive discussion.
  • Additionally, SXSW EDU has unveiled a series of new Featured Sessions taking place during the convening from March 4-7, 2024.

Steel Partners Holdings Reports Third Quarter Financial Results and Declares Quarterly Distribution on its Series A Preferred Units

Retrieved on: 
Thursday, November 9, 2023
Other Professional Services, Asset Management, Professional Services, Finance, Tax, Financial services, Supply chain, CRT, Steel Connect, Repurchase agreement, Energy, EBITDA, Partnership, E series of preferred numbers, Capital expenditure, Associate company, Building material, Investment, Service provider, Financial services in Japan, ERP, Marketing, Retail, Cryptocurrency, Life insurance, Airline, Corporation

SG&A for the nine months ended September 30, 2023 increased $95,653, or 34.1%, as compared to the same period last year.

Key Points: 
  • SG&A for the nine months ended September 30, 2023 increased $95,653, or 34.1%, as compared to the same period last year.
  • The Company's effective tax rate was (1.4)% and 29.4% for the nine months ended September 30, 2023 and 2022, respectively.
  • The fluctuations for these periods were primarily due to the changes in fair value of the Company's investment in Steel Connect.
  • As of September 30, 2023, there were approximately 969,632 common units that may yet be purchased under the Repurchase Program.

Impulse Dynamics Receives Full-Body MRI-Conditional Approval for Optimizer Smart Mini System

Retrieved on: 
Monday, October 30, 2023
NYHA, FDA, MRI, Heart failure, Heart, CRT, Physician, Cardiac resynchronization therapy, Quality of life, CCM, HF, Mathematical optimization, Patient, Google Images, Medical imaging, Medical device

MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA).

Key Points: 
  • MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA).
  • The Optimizer Smart Mini system delivers the company’s proprietary CCM® therapy.
  • The approval for use with full-body MRI covers new patients adopting CCM therapy as well as existing Optimizer Smart Mini users.
  • Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system.

Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology

Retrieved on: 
Wednesday, October 25, 2023
NYHA, American College, Food, CRT, LVEF, Cardiac resynchronization therapy, Heel, McCutcheon, ASX, Achilles, Institutional review board, Coronary sinus, Wise, Journal, Cardiology, Patient, Food and Drug Administration, Heart failure, MD, Nissan Micra, JACC, Research, Growth, QRS, FDA, IRB, Cardiac electrophysiology, Journal of the American College of Cardiology, EBR, Medtronic, Failure, Medical device, Television, Pharmaceutical industry

The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.

Key Points: 
  • The positive results published in JACC are based on a 1-year follow-up of the first-in-human implantation in the US of totally leadless CRT pacing utilizing the Micra™ leadless pacing system in the right ventricle in conjunction with EBR's investigational WiSE® CRT Electrode in the left ventricle of the heart.
  • This first use in the US of the WiSE CRT System as a first-line therapy is a future market expansion opportunity for EBR.
  • "It's great to see these positive results being published in a world-leading cardiology journal, such as The Journal of the American College of Cardiology," said John McCutcheon, President & CEO of EBR Systems.
  • "This case study highlights the potential of totally leadless CRT for patients struggling with traditional CRT, but also beyond these patient groups, the 64 million heart failure patients across the globe."